checkAd

Angle PLC Announces Issue of Equity

Exercise of Options and Total Voting RightsGUILDFORD, SURREY / ACCESSWIRE / September 30, 2022 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and …

Exercise of Options and Total Voting Rights

GUILDFORD, SURREY / ACCESSWIRE / September 30, 2022 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 8,333 new ordinary shares of £0.10 each ("New Ordinary Shares") in the Company. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.

An application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective, and trading will commence at 8.00 a.m. on 5 October 2022. Following Admission, the total number of Ordinary Shares in issue, and therefore the total number of voting rights, will be 260,498,881.

For further information:

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations

Berenberg (NOMAD and Joint Broker)

Toby Flaux, Ciaran Walsh, Milo Bonser

+44 (0) 20 3207 7800

Jefferies (Joint Broker)

Max Jones, Thomas Bective

+44 (0) 20 7029 8000

FTI Consulting

Simon Conway, Ciara Martin
Matthew Ventimiglia (US)

+44 (0) 203 727 1000

+1 (212) 850 5624

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology known as the Parsortix® system and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

Seite 1 von 4


Wertpapier



0 Kommentare
Nachrichtenquelle: Accesswire
 |  110   |   |   

Schreibe Deinen Kommentar

Disclaimer

Angle PLC Announces Issue of Equity Exercise of Options and Total Voting RightsGUILDFORD, SURREY / ACCESSWIRE / September 30, 2022 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and …

Nachrichten des Autors

2605 Leser
250 Leser
224 Leser
179 Leser
172 Leser
167 Leser
167 Leser
160 Leser
146 Leser
140 Leser
2605 Leser
821 Leser
470 Leser
394 Leser
378 Leser
332 Leser
308 Leser
250 Leser
243 Leser
229 Leser
4528 Leser
2605 Leser
1731 Leser
1234 Leser
1125 Leser
942 Leser
906 Leser
900 Leser
821 Leser
766 Leser